FDA approves second PrEP drug to prevent HIV infection

The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and adolescents weighing at least 75lbs for the prevention of HIV infection.

The safety and efficacy of the drug were evaluated in the randomised, double-blind multinational DISCOVER trial in 5387 HIV-negative men and transgender women who have sex with men. The trial compared the once-daily Descovy to Truvada.

read more

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.